MBX Biosciences, Inc 10-Q for FY2026 Q3
MBX Biosciences, Inc. (MBX)
10-Q
2026-11-09
For: 2026-09-30
View Original
Added on
November 09, 2026
About this 10-Q
MBX Biosciences, Inc filed this 10-Q on November 9, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).
MBX Biosciences reported $481.6 million in cash, cash equivalents and marketable securities at September 30, 2026, expecting existing resources to fund operations into 2029. Nine-month net loss was $123.0 million, versus $64.9 million in 2025. AI summary
Headline figures
Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Net loss
- $62.42M
- compared with a net loss of $21.62M a year earlier
- Diluted EPS
- -$1.29
- compared with -$0.63 a year earlier